Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Drug Shortage Senate Draft: FDA Told To Look For Impact Before Leaping Into Enforcement

Executive Summary

Proposal would require shortage consideration before FDA issues an enforcement action, which could ensure enforcement and shortage staff continue talking.

Advertisement

Related Content

Orphan Antibiotics? Woodcock Says It May Be Possible If IDSA’s New Pathway Is Implemented
Drug Shortage Legislation: Sen. Blumenthal Calls For More Extensive Effort
Drug Shortage Provisions In Draft PDUFA Bill Would Expedite Major Manufacturing Changes
PDUFA Draft Bill Would Broaden FDA’s Mission, Make Guidance Development More Public
Medicare Reimbursement Rate Targeted As Culprit For Drug Shortages
Drug Shortage Fixes Migrating Toward Economics
Drug Shortages: Can The Blame Game Help Find Solutions?
To Prevent Drug Shortages, Don't Look To Inspections, FDA Says
Inspection Improvements Could Help Fight Drug Shortages, Hospital Group Says

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS054362

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel